Product Information
DEXTROAMP-AMPHET ER 30 MG CAP is a generic product labeled by Actavis Pharma, Inc., priced at $0.4656 per EA under NDC 00228306111. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jun 22, 2012. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
DEXTROAMP-AMPHET ER 30 MG CAP
Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfateStrength
7.5; 7.5; 7.5; 7.5 mg/1; mg/1; mg/1; mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00228306111
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA077302FDA Approved
6/22/2012
TE Code
AB1
On Market Since
6/22/2012
Pharmacological Classes
Price Statistics
The NADAC for DEXTROAMP-AMPHET ER 30 MG CAP has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 88.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4656 per EA |
|---|---|
| All-time high | $3.9537 (Jan 15, 2014) |
| All-time low | $0.3360 (May 22, 2024) |
| 52-week high | $0.5596 |
| 52-week low | $0.4621 |
| Median price | $1.5374 |
| Average price | $1.7343 |
| Largest weekly change | +61.4% (Jun 19, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DEXTROAMP-AMPHET ER 30 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for DEXTROAMP-AMPHET ER 30 MG CAP, manufactured by Actavis Pharma, Inc., is $0.4656 per EA (NDC 00228306111), effective Sep 30, 2026.
How has the price of DEXTROAMP-AMPHET ER 30 MG CAP changed over time?
Over the history we have for it, the NADAC for DEXTROAMP-AMPHET ER 30 MG CAP has declined 88.1%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for DEXTROAMP-AMPHET ER 30 MG CAP?
Since Nov 28, 2013, the NADAC for DEXTROAMP-AMPHET ER 30 MG CAP has ranged from a low of $0.3360 (May 22, 2024) to a high of $3.9537 (Jan 15, 2014), with a median of $1.5374 per EA.
Are there cheaper alternatives to DEXTROAMP-AMPHET ER 30 MG CAP?
No other NADAC-published product currently shares the active ingredient and strength of DEXTROAMP-AMPHET ER 30 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DEXTROAMP-AMPHET ER 30 MG CAP?
DEXTROAMP-AMPHET ER 30 MG CAP (NDC 00228306111) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.